Intoxication with Phenprocoumon (Marcoumar) Pharmacokinetics and Side Effects

K Seiler; F Duckert

doi:10.1055/s-0038-1653541

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1969; 21(02): 320-324
DOI: 10.1055/s-0038-1653541

Originalarbeiten - Original Articles - Travaux Originaux

Schattauer GmbH

Intoxication with Phenprocoumon (Marcoumar) Pharmacokinetics and Side Effects

Authors

K Seiler

¹Blood Coagulation and Fibrinolysis Laboratory (Head: Dr. F. Duckert) of the University Department of Medicine (Head: Prof .Dr. F .Koller), Bürgerspital, Basel, Switzerland
F Duckert

¹Blood Coagulation and Fibrinolysis Laboratory (Head: Dr. F. Duckert) of the University Department of Medicine (Head: Prof .Dr. F .Koller), Bürgerspital, Basel, Switzerland

Abstract

Summary

A case of severe Marcoumar intoxication is described. Eleven hours after the intake a plasma concentration of 15.75 µg/ml was found which corresponds approximately to the 5-fold therapeutic concentration. Repeated administration of vitamin K₁ made it possible to avoid extreme lowering of the activity of the clotting factors II, VII and X and to prevent bleeding. Side effects were not observed. The biologic half-life of Phenprocoumon has been found to be shortened at high plasma concentration (3.7 instead of 5.9 days). It is probable that in extreme concentration the drug is less strongly bound to the plasma proteins.

Full Text

References

References
1 Aggeler P. M, O’Reilly R. A. The pharmacological basis of oral anticoagulant therapy. In: Pathogenesis and Treatment of thromboembolic Diseases. International Symposium Basle. Ed. Koller F, Duckert F, Streuli F. 227 F. K. Schattauer; Stuttgart: 1965
2 Baumgartner H. R, Gronquist M, Wobmann P, Streuli F, Duckert F. Die Messung der Thrombocytenadhäsivität. Schweiz, med. Wschr 97 Nr. 50, 1674 1967;
3 Douglas A. S. Anticoagulant therapy. 159 Blackwell Scientific Publications; Oxford: 1962
4 Duckert F. Mécanisme de la Coagulation. Röntgen und Laboratoriumspraxis 13 L 224 1960;
5 Hellem A. J. The adhesiveness of human blood platelets in vitro. Thesis. Scand. J. clin. Lab. Invest 12 Suppl. 51 1960;
6 Jürgens R. Experimentelle Untersuchungen über das Antikoagulans Marcoumar 3-(Phenyl- propyl)-4-oxycumarin und seinen Antagonisten Konakion (synthetisches Vitamin KJ. Schweiz, med. Wschr 83: 20 471 1953;
7 Shapiro S. Complications of Treatment. In: Clinical Anticoagulant Therapy. Ed. Myron V. i. gran. 275 Lea and Febinger; Philadelphia: 1965
8 Seiler K, Duckert F. Properties of 3-(l-phenyl-propyl)-4-oxycoumarin (Marcoumar^®) in the plasma when tested in normal cases and under the influence of drugs. Thrombos. Diathes. haemorrh. (Stuttg) 19: 389 1968;
9 Zuckschwerdt L, Thies H. A. Nebenwirkungen von Antikoagulantien und Fibrinolytika. VII. Hamburger Symposium über Blutgerinnung. F. K. Schattauer; Stuttgart: 1965